PRIM joins forces with the HM Hospitals Research Foundation to enhance the early detection of neurodegenerative diseases
Both institutions have agreed to conduct research in order to corroborate the usefulness of the ocular motility of the Oscann™ device for the early and progressive diagnosis of Alzheimer’s and Parkinson’s disease.
The research will be carried out at the HM Madrid University Hospital, and it is estimated that the cohort study will involve around 200 patients.
HM Hospitals, through the HM Hospitals Research Foundation (FiHM), and PRIM have reached a framework collaboration agreement by which both parties set up an alliance with the main purpose to advance and enhance the early detection of neurodegenerative diseases, specifically Alzheimer’s and Parkinson’s disease.
The signing of this framework agreement took place at the HM Hospitals Headquarters and was attended by Jorge Prim, vice-president of PRIM; Fernando Oliveros, Executive Director of PRIM; Dr. Juan Abarca Cidón, the president of HM Hospitals; and the scientific director of the HM Hospitals Research Foundation, Dr. José María Castellano.
Jorge PRIM, vice-president of PRIM, stated that, “this agreement means setting up a collaboration framework with a leading national hospital that will ultimately be for the benefit of patients, improving their health and the quality of the care they receive, granting them access to the best possible medical technology available “.
For HM Hospitals and its Foundation, further knowledge and the early diagnosis of neurodegenerative diseases are key issues when it comes to anticipating symptoms and providing patients with better therapeutic options. The institution stated that “by joining with PRIM in this project there is also a guarantee of success due to the cutting-edge technology it can offer”.
From left to right: Dr. Jesús Peláez, Corporate Medical Director of HM Hospitals; Dr. José María Castellano, Scientific Director of the HM Hospitals Research Foundation; Jorge Prim Martínez, Vice-President of PRIM; Dr. Juan Abarca Cidón, President of HM Hospitals; Fernando Oliveros Arreaga, Executive Director of PRIM; Javier del Río Sastre, Director of Business Development; Francisco Aldea, Managing Director of the HM Hospitals Research Foundation.
Specifically, both institutions agree to develop research in order to corroborate the usefulness of the ocular motility of the Oscann™ device for the early and progressive diagnosis of Alzheimer’s and Parkinson’s disease.
The HM Madrid University Hospital will be the chosen centre for the research, as it houses the HM CINAC Memory Disorders Unit, led by Dr. Javier Olazarán, who specialises in the approach and research of dementia and other neurodegenerative diseases. The research will include around 200 patients and will be completed in 2025.
This post is also available in: Spanish
